Loading...
Market
In how many countries will Kebilidi be approved by December 31, 2025?
2
Resolution / Starting Odds
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Global regulatory approval announcements and PTC Therapeutics' press releases
Story
PTC Therapeutics' Kebilidi Gene Therapy for AADC Deficiency Gains FDA Approval, Stock Up 3.3%
Nov 14, 2024, 01:23 PM
PTC Therapeutics has received FDA approval for its gene therapy targeting aromatic L-amino acid decarboxylase (AADC) deficiency, an ultra-rare and fatal enzyme disorder. The therapy, named Kebilidi, is the first of its kind approved for treating both adult and pediatric patients with this condition. Following the announcement, PTC Therapeutics' stock price rose by 3.3% in pre-market trading.
View original story
Similar markets
Europe • 25%
Asia • 25%
South America • 25%
Other • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
31 or more countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
Yes • 50%
No • 50%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%
0 countries • 25%
1 to 3 countries • 25%
4 to 6 countries • 25%
More than 6 countries • 25%
Less than 5 • 33%
5 to 10 • 34%
More than 10 • 33%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%